Live at IDWeek 2013

HIV Prophylaxis with twice-daily lopinavir/ritonavir was well tolerated in high-risk neonates without adverse drug events, as reported at IDWeek 2013.

Girls 9-13 years with HIV who received the quadrivalent human papillomavirus vaccine (qHPV) had significantly lower peak geometric mean titers (GMT) vs. same-aged girls without HIV infection, a study presented at IDWeek 2013 has found.

The completion rate of a 12-dose, 3-month isoniazid/rifapentine (3HP) regimen in this study (83.7%) is comparable to its completion rate in Study 26 (82.1%), and is significantly higher than the average 55.0% completion rate for the 9-month isoniazid regimen that was reported in Arkansas for the past 5 years, according to results presented at IDWeek 2013.

Pyrazinamide is safe in elderly patients >80 years old not experiencing malnourishment, low-grade ADL, and previously elevated liver enzymes, as presented by Ryutaro Tanizaki, MD, from the National Center for Global Health and Medicine, Tokyo, Japan at IDWeek 2013.

Fidaxomicin was highly effective in patients with cancer treated for the first episode of C. difficile infection (CDI) after failure of standard therapy and in patients with recurrent CDI, results of a study presented at IDWeek 2013.

Distribution patterns of species was similar in hospital-associated (HA) and community-associated (CA) intra-abdominal infections (IAI), according to study results presented at IDWeek 2013.

In HIV-seropositive patients on antiretroviral therapy (ART) with non-infectious diarrhea, crofelemer 125mg twice daily was well tolerated with a low incidence of adverse events and no clinical deterioration of immune status, study investigators reported at IDWeek 2013.

Once-daily oral combination of daclatasvir (DCV) + sofosbuvir (SOF) with or without ribavirin (RBV) achieved sustained virologic response (SVR) in chronic HCV GT1 infected patients with prior telaprevir (TVR) or boceprevir (BOC) + peginterferon/ribavirin treatment failures.

Antifungal prophylaxis is associated with significant reduction in induction mortality rates in pediatric patients with acute myeloid leukemia (AML) and reduced supportive care resources utilization.